Loading…

N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy

Anandamide (AEA) analogs show fair effects in counteracting the deterioration of Alzheimer's disease (AD). Our previous studies demonstrated that AEA analog-N-linoleyltyrosine (NITyr) exerted significant activities. In our current research, the role and mechanisms of NITyr were assessed in APP/...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacological sciences 2021-12, Vol.147 (4), p.315-324
Main Authors: Long, Chun-mei, Zheng, Qi-xue, Zhou, Yi, Liu, Yuan-ting, Gong, Liu-ping, Zeng, Ying-chun, Liu, Sha
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3
cites cdi_FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3
container_end_page 324
container_issue 4
container_start_page 315
container_title Journal of pharmacological sciences
container_volume 147
creator Long, Chun-mei
Zheng, Qi-xue
Zhou, Yi
Liu, Yuan-ting
Gong, Liu-ping
Zeng, Ying-chun
Liu, Sha
description Anandamide (AEA) analogs show fair effects in counteracting the deterioration of Alzheimer's disease (AD). Our previous studies demonstrated that AEA analog-N-linoleyltyrosine (NITyr) exerted significant activities. In our current research, the role and mechanisms of NITyr were assessed in APP/PS1 mice mimicking the AD model. NITyr improved motor coordination in the rotarod test (RRT) and ameliorated spatial memory in the Morris water maze (MWM) but did not increase spontaneous locomotor activity in the open field test (OFT). In addition, NITyr protected neurons against β-amyloid (Aβ) injury via hematoxylin-eosin (HE) and Nissl staining. Moreover, the related biochemical indexes showed that NITyr reduced the levels of Aβ40 and Aβ42 in the hippocampus but did not affect the expression of p-APP and β-secretase 1 (BACE1). Furthermore, the autophagy inhibitor 3-methyladenine (3 MA) attenuated the effect of NITyr on animal behaviors and neurons. Meanwhile, NITyr upregulated the expression levels of LC3-II and Beclin-1, which were weakened by AM630 (an antagonist of CB2 receptor and a weak partial agonist of CB1 receptors). AM630 also weakened the role of NITyr in animal behaviors. Thus, NITyr improved behavioral impairment and neural loss by inducing autophagy mainly mediated by the CB2 receptor, and weakly mediated by the CB1 receptor.
doi_str_mv 10.1016/j.jphs.2021.08.008
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8f3f3fd379a1485b80c8ab69110d28e9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1347861321000839</els_id><doaj_id>oai_doaj_org_article_8f3f3fd379a1485b80c8ab69110d28e9</doaj_id><sourcerecordid>2583443150</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSMEoqXwBTggH7kk9dj540hcqqpApQpWAs6WY0-2jrJ2sJ1V99vjZcsekQ8ejd78RvNeUbwHWgGF9nqqpuUxVowyqKioKBUvikvgdVeKthYvzzXwi-JNjBOlTOS518UFr9uWN8Avi6dv5Wydn_Ewp0Pw0Tok-IQhReJwDX4JPqFOdp_b45irSKwjN5vN9eYHkBSUi1t0VpOd1Uj2VhGtnFNDZlpDAmpckg_lDo1VCQ1Ra_LLo9oe3havRjVHfPf8XxW_Pt_9vP1aPnz_cn9781Dquqep1E3ToTIIvW5xoNAjDEorpiiMpqkHYNC10JlaKzN2lDMAUXNosIG2RTbwq-L-xDVeTXIJdqfCQXpl5d-GD1upQrJ6RilGnp_hXa-gFs0gqBZqaHsAapjAPrM-nljZld8rxiR3NmqcZ-XQr1GyRvD6uJ1mKTtJdTY1BhzPq4HKY3pyksf05DE9SYXM6eWhD8_8dciOnUf-xZUFn04CzI7tLQYZtUWns7vZ6pRPsv_j_wHtlK0q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2583443150</pqid></control><display><type>article</type><title>N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy</title><source>ScienceDirect Journals</source><creator>Long, Chun-mei ; Zheng, Qi-xue ; Zhou, Yi ; Liu, Yuan-ting ; Gong, Liu-ping ; Zeng, Ying-chun ; Liu, Sha</creator><creatorcontrib>Long, Chun-mei ; Zheng, Qi-xue ; Zhou, Yi ; Liu, Yuan-ting ; Gong, Liu-ping ; Zeng, Ying-chun ; Liu, Sha</creatorcontrib><description>Anandamide (AEA) analogs show fair effects in counteracting the deterioration of Alzheimer's disease (AD). Our previous studies demonstrated that AEA analog-N-linoleyltyrosine (NITyr) exerted significant activities. In our current research, the role and mechanisms of NITyr were assessed in APP/PS1 mice mimicking the AD model. NITyr improved motor coordination in the rotarod test (RRT) and ameliorated spatial memory in the Morris water maze (MWM) but did not increase spontaneous locomotor activity in the open field test (OFT). In addition, NITyr protected neurons against β-amyloid (Aβ) injury via hematoxylin-eosin (HE) and Nissl staining. Moreover, the related biochemical indexes showed that NITyr reduced the levels of Aβ40 and Aβ42 in the hippocampus but did not affect the expression of p-APP and β-secretase 1 (BACE1). Furthermore, the autophagy inhibitor 3-methyladenine (3 MA) attenuated the effect of NITyr on animal behaviors and neurons. Meanwhile, NITyr upregulated the expression levels of LC3-II and Beclin-1, which were weakened by AM630 (an antagonist of CB2 receptor and a weak partial agonist of CB1 receptors). AM630 also weakened the role of NITyr in animal behaviors. Thus, NITyr improved behavioral impairment and neural loss by inducing autophagy mainly mediated by the CB2 receptor, and weakly mediated by the CB1 receptor.</description><identifier>ISSN: 1347-8613</identifier><identifier>EISSN: 1347-8648</identifier><identifier>DOI: 10.1016/j.jphs.2021.08.008</identifier><identifier>PMID: 34663513</identifier><language>eng</language><publisher>Japan: Elsevier B.V</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer Disease - metabolism ; Alzheimer Disease - psychology ; Amyloid beta-Peptides - metabolism ; Amyloid beta-Protein Precursor ; Animals ; APP/PS1 transgenic mice ; Autophagy ; Autophagy - drug effects ; Cannabinoid receptor ; Disease Models, Animal ; Hippocampus - metabolism ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; N-linoleyltyrosine ; Neuroprotection ; Neuroprotective Agents ; Presenilin-1 ; Psychomotor Performance - drug effects ; Receptor, Cannabinoid, CB1 - metabolism ; Receptor, Cannabinoid, CB2 - metabolism ; Receptors, Cannabinoid ; Spatial Memory - drug effects ; Tyrosine - analogs &amp; derivatives ; Tyrosine - pharmacology</subject><ispartof>Journal of pharmacological sciences, 2021-12, Vol.147 (4), p.315-324</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Production and hosting by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3</citedby><cites>FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1347861321000839$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34663513$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Long, Chun-mei</creatorcontrib><creatorcontrib>Zheng, Qi-xue</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Liu, Yuan-ting</creatorcontrib><creatorcontrib>Gong, Liu-ping</creatorcontrib><creatorcontrib>Zeng, Ying-chun</creatorcontrib><creatorcontrib>Liu, Sha</creatorcontrib><title>N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy</title><title>Journal of pharmacological sciences</title><addtitle>J Pharmacol Sci</addtitle><description>Anandamide (AEA) analogs show fair effects in counteracting the deterioration of Alzheimer's disease (AD). Our previous studies demonstrated that AEA analog-N-linoleyltyrosine (NITyr) exerted significant activities. In our current research, the role and mechanisms of NITyr were assessed in APP/PS1 mice mimicking the AD model. NITyr improved motor coordination in the rotarod test (RRT) and ameliorated spatial memory in the Morris water maze (MWM) but did not increase spontaneous locomotor activity in the open field test (OFT). In addition, NITyr protected neurons against β-amyloid (Aβ) injury via hematoxylin-eosin (HE) and Nissl staining. Moreover, the related biochemical indexes showed that NITyr reduced the levels of Aβ40 and Aβ42 in the hippocampus but did not affect the expression of p-APP and β-secretase 1 (BACE1). Furthermore, the autophagy inhibitor 3-methyladenine (3 MA) attenuated the effect of NITyr on animal behaviors and neurons. Meanwhile, NITyr upregulated the expression levels of LC3-II and Beclin-1, which were weakened by AM630 (an antagonist of CB2 receptor and a weak partial agonist of CB1 receptors). AM630 also weakened the role of NITyr in animal behaviors. Thus, NITyr improved behavioral impairment and neural loss by inducing autophagy mainly mediated by the CB2 receptor, and weakly mediated by the CB1 receptor.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - psychology</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Amyloid beta-Protein Precursor</subject><subject>Animals</subject><subject>APP/PS1 transgenic mice</subject><subject>Autophagy</subject><subject>Autophagy - drug effects</subject><subject>Cannabinoid receptor</subject><subject>Disease Models, Animal</subject><subject>Hippocampus - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic</subject><subject>N-linoleyltyrosine</subject><subject>Neuroprotection</subject><subject>Neuroprotective Agents</subject><subject>Presenilin-1</subject><subject>Psychomotor Performance - drug effects</subject><subject>Receptor, Cannabinoid, CB1 - metabolism</subject><subject>Receptor, Cannabinoid, CB2 - metabolism</subject><subject>Receptors, Cannabinoid</subject><subject>Spatial Memory - drug effects</subject><subject>Tyrosine - analogs &amp; derivatives</subject><subject>Tyrosine - pharmacology</subject><issn>1347-8613</issn><issn>1347-8648</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kU9v1DAQxSMEoqXwBTggH7kk9dj540hcqqpApQpWAs6WY0-2jrJ2sJ1V99vjZcsekQ8ejd78RvNeUbwHWgGF9nqqpuUxVowyqKioKBUvikvgdVeKthYvzzXwi-JNjBOlTOS518UFr9uWN8Avi6dv5Wydn_Ewp0Pw0Tok-IQhReJwDX4JPqFOdp_b45irSKwjN5vN9eYHkBSUi1t0VpOd1Uj2VhGtnFNDZlpDAmpckg_lDo1VCQ1Ra_LLo9oe3havRjVHfPf8XxW_Pt_9vP1aPnz_cn9781Dquqep1E3ToTIIvW5xoNAjDEorpiiMpqkHYNC10JlaKzN2lDMAUXNosIG2RTbwq-L-xDVeTXIJdqfCQXpl5d-GD1upQrJ6RilGnp_hXa-gFs0gqBZqaHsAapjAPrM-nljZld8rxiR3NmqcZ-XQr1GyRvD6uJ1mKTtJdTY1BhzPq4HKY3pyksf05DE9SYXM6eWhD8_8dciOnUf-xZUFn04CzI7tLQYZtUWns7vZ6pRPsv_j_wHtlK0q</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Long, Chun-mei</creator><creator>Zheng, Qi-xue</creator><creator>Zhou, Yi</creator><creator>Liu, Yuan-ting</creator><creator>Gong, Liu-ping</creator><creator>Zeng, Ying-chun</creator><creator>Liu, Sha</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20211201</creationdate><title>N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy</title><author>Long, Chun-mei ; Zheng, Qi-xue ; Zhou, Yi ; Liu, Yuan-ting ; Gong, Liu-ping ; Zeng, Ying-chun ; Liu, Sha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - psychology</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Amyloid beta-Protein Precursor</topic><topic>Animals</topic><topic>APP/PS1 transgenic mice</topic><topic>Autophagy</topic><topic>Autophagy - drug effects</topic><topic>Cannabinoid receptor</topic><topic>Disease Models, Animal</topic><topic>Hippocampus - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic</topic><topic>N-linoleyltyrosine</topic><topic>Neuroprotection</topic><topic>Neuroprotective Agents</topic><topic>Presenilin-1</topic><topic>Psychomotor Performance - drug effects</topic><topic>Receptor, Cannabinoid, CB1 - metabolism</topic><topic>Receptor, Cannabinoid, CB2 - metabolism</topic><topic>Receptors, Cannabinoid</topic><topic>Spatial Memory - drug effects</topic><topic>Tyrosine - analogs &amp; derivatives</topic><topic>Tyrosine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Long, Chun-mei</creatorcontrib><creatorcontrib>Zheng, Qi-xue</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Liu, Yuan-ting</creatorcontrib><creatorcontrib>Gong, Liu-ping</creatorcontrib><creatorcontrib>Zeng, Ying-chun</creatorcontrib><creatorcontrib>Liu, Sha</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of pharmacological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Long, Chun-mei</au><au>Zheng, Qi-xue</au><au>Zhou, Yi</au><au>Liu, Yuan-ting</au><au>Gong, Liu-ping</au><au>Zeng, Ying-chun</au><au>Liu, Sha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy</atitle><jtitle>Journal of pharmacological sciences</jtitle><addtitle>J Pharmacol Sci</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>147</volume><issue>4</issue><spage>315</spage><epage>324</epage><pages>315-324</pages><issn>1347-8613</issn><eissn>1347-8648</eissn><abstract>Anandamide (AEA) analogs show fair effects in counteracting the deterioration of Alzheimer's disease (AD). Our previous studies demonstrated that AEA analog-N-linoleyltyrosine (NITyr) exerted significant activities. In our current research, the role and mechanisms of NITyr were assessed in APP/PS1 mice mimicking the AD model. NITyr improved motor coordination in the rotarod test (RRT) and ameliorated spatial memory in the Morris water maze (MWM) but did not increase spontaneous locomotor activity in the open field test (OFT). In addition, NITyr protected neurons against β-amyloid (Aβ) injury via hematoxylin-eosin (HE) and Nissl staining. Moreover, the related biochemical indexes showed that NITyr reduced the levels of Aβ40 and Aβ42 in the hippocampus but did not affect the expression of p-APP and β-secretase 1 (BACE1). Furthermore, the autophagy inhibitor 3-methyladenine (3 MA) attenuated the effect of NITyr on animal behaviors and neurons. Meanwhile, NITyr upregulated the expression levels of LC3-II and Beclin-1, which were weakened by AM630 (an antagonist of CB2 receptor and a weak partial agonist of CB1 receptors). AM630 also weakened the role of NITyr in animal behaviors. Thus, NITyr improved behavioral impairment and neural loss by inducing autophagy mainly mediated by the CB2 receptor, and weakly mediated by the CB1 receptor.</abstract><cop>Japan</cop><pub>Elsevier B.V</pub><pmid>34663513</pmid><doi>10.1016/j.jphs.2021.08.008</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1347-8613
ispartof Journal of pharmacological sciences, 2021-12, Vol.147 (4), p.315-324
issn 1347-8613
1347-8648
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_8f3f3fd379a1485b80c8ab69110d28e9
source ScienceDirect Journals
subjects Alzheimer Disease - drug therapy
Alzheimer Disease - metabolism
Alzheimer Disease - psychology
Amyloid beta-Peptides - metabolism
Amyloid beta-Protein Precursor
Animals
APP/PS1 transgenic mice
Autophagy
Autophagy - drug effects
Cannabinoid receptor
Disease Models, Animal
Hippocampus - metabolism
Mice
Mice, Inbred C57BL
Mice, Transgenic
N-linoleyltyrosine
Neuroprotection
Neuroprotective Agents
Presenilin-1
Psychomotor Performance - drug effects
Receptor, Cannabinoid, CB1 - metabolism
Receptor, Cannabinoid, CB2 - metabolism
Receptors, Cannabinoid
Spatial Memory - drug effects
Tyrosine - analogs & derivatives
Tyrosine - pharmacology
title N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A29%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=N-linoleyltyrosine%20exerts%20neuroprotective%20effects%20in%20APP/PS1%20transgenic%20mice%20via%20cannabinoid%20receptor-mediated%20autophagy&rft.jtitle=Journal%20of%20pharmacological%20sciences&rft.au=Long,%20Chun-mei&rft.date=2021-12-01&rft.volume=147&rft.issue=4&rft.spage=315&rft.epage=324&rft.pages=315-324&rft.issn=1347-8613&rft.eissn=1347-8648&rft_id=info:doi/10.1016/j.jphs.2021.08.008&rft_dat=%3Cproquest_doaj_%3E2583443150%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2583443150&rft_id=info:pmid/34663513&rfr_iscdi=true